|
Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio. |
|
|
Honoraria - AstraZeneca; Proacta |
Consulting or Advisory Role - Celldex; Ipsen; Proacta |
Research Funding - Proacta |
Patents, Royalties, Other Intellectual Property - Aix-Marseille University |
Other Relationship - Proacta |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Proacta |
Consulting or Advisory Role - Proacta |
|
|
Consulting or Advisory Role - Abbvie; Agios; Amgen; Celgene; Celldex; Cortice Biosciences; CytRx Corporation; Lpath; Nektar; NewGen Therapeutics; Novartis; Novocure; Oxigene; Proximagen; Roche/Genentech; StemCycle; Tocagen; Upsher-Smith; VBL Therapeutics; Wellcome Trust |
|
|
|
Consulting or Advisory Role - Proacta |
|
|
Honoraria - Abbvie; Chugai Pharma; Eisai; MSD |
Consulting or Advisory Role - Novocure; Roche |
Research Funding - Chugai Pharma (Inst); MSD (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Proacta |
Travel, Accommodations, Expenses - Proacta |
|
|
Consulting or Advisory Role - Proacta |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; LEO Pharma |
Consulting or Advisory Role - Amgen; Novartis; Pfizer; Roche canada; Sanofi |
Travel, Accommodations, Expenses - Amgen; Roche/Genentech; Sanofi |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Proacta |
|
|
|
|
|
Employment - Roche/Genentech |
Stock and Other Ownership Interests - Roche/Genentech |
Patents, Royalties, Other Intellectual Property - Proacta |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Proacta |
|
|
Honoraria - MSD Oncology; Prime Oncology; Roche/Genentech |
Consulting or Advisory Role - Celldex; Roche/Genentech |
Research Funding - Apogenix (Inst); Boehringer Ingelheim (Inst); Roche (Inst) |
|
|
|
Research Funding - Novartis |
Travel, Accommodations, Expenses - Chugai Pharma; Pierre Fabre |